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A B S T R A C T
The aim of this study was to explore the expression of cancer/testis tumor associated antigens (C/T TAAs) MAGE-A
3/4 and NY-ESO-1 in lung squamous cell carcinoma and adenocarcinoma, and to evaluate their association with the
standard clinical-pathological features of surgically treated lung cancer patients. The study included 80 patients with
non-small cell lung cancer (40 adenocarcinomas, 40 squamous cell carcinomas) who had undergone surgery in the pe-
riod between 2002 and 2005. The MAGE-A3/4 and NY-ESO-1 antigen expression was analyzed immunohistochemically
(IHC). The results showed MAGE-A3/4 and NY-ESO-1 positive staining in 65.1% and 23.3% of squamous cell carcino-
mas and 18.9% and 10.8% of adenocarcinomas, respectively. A statistically higher MAGE-A3/4 expression was observed
in planocellular bronchial carcinoma (p<0.001), while no difference was found in the expression of NY-ESO-1 in adeno-
carcinoma and planocellular carcinoma (p=0.144). A significant association was found between the MAGE-A3/4 expres-
sion and presence of tumor necrosis in squamous cell cancer specimens (p=0.001), but not in adenocarcinoma (p=0.033).
A statistically significant association was noted between the NY-ESO-1 expression and positive hilar and mediastinal
lymph nodes in adenocarcinoma (p=0.025) whereas it was not the case in squamous cell carcinoma. Non-small cell lung
cancer frequently expresses cancer/testis tumor associated antigens. Our results demonstrate that the MAGE-A3/4 and
NY-ESO-1 expression was significant associated with prognostic factors of poor outcome of disease (presence of tumor
necrosis and lymph node metastasis). As C/T antigens are important for inducing a specific immune reaction in lung
cancer patients, there is an intention to form a subgroup of patients in the future, whose treatment would be enhanced by
specific immunotherapy based on the observed scientific results.
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Introduction
Lung cancer is the most frequent cause of cancer
death and its incidence has been steadily increasing dur-
ing recent decades 1. The number of new cases is increas-
ing in rate of about 3% annually 2. Despite the advances
in early detection of lung cancer, the overall 5-year sur-
vival still remains disappointing. Cigarette smoking re-
mains the major risk factor on the incidence of this can-
cer. Today we acknowledge that tobacco smoking is the
principal cause of lung cancer, accounting for 90% of lung
cancer deaths in men and approximately 60% in woman3.
Adenocarcinoma is the most frequent histological type
(50%) and squamous cell carcinoma, previously the most
common, accounts for approximately one third of non-
-small cell lung cancer (NSCLC)4. Small cell carcinoma
accounts for 15–20% of lung cancers.
Surgery remains the initial treatment for patients
with early stage non-small cell cancer, but additional
therapy is necessary because of high rates of distant and
local disease recurrence after surgical resection5. The re-
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sults of large randomized studies have demonstrated
that adjuvant chemotherapy prolongs overall survival by
approximately 5% at 5 years in patients with early-stage
non-small cell lung carcinoma6. Radiotherapy constitu-
tes one of the main treatment modalities in lung cancer
and is indicated in around three-quarters of all lung can-
cer cases7.
Cancer/testis tumor associated antigens (C/T TAA-s)
present one of the tumor antigen groups, characterized
by outstanding immunogenicity, which is why there are
numerous ongoing clinical research studies examining
vaccines based on these antigens. They are normally ex-
pressed in gametes8 and trophoblasts9, but only excep-
tionally in other healthy tissues. Cancer-testis antigens
were recognized as a group of attractive targets for can-
cer immunotherapy because of their expression in nu-
merous human neoplasms, among which there is lung
cancer10–15. Their potential relevance as tumor markers
has also been underlined. The genes, which code the mel-
anoma antigens MAGE (Melanoma Antigen E) and NY-
-ESO-1 (New York Oesophageal Squamous Cell Cancer),
are expressed in numerous malignant neoplasms, includ-
ing lung cancer16–19.
The most studied TAAs subgroup is the MAGE-A
family of C/T antigens and comprises more than 25
genes. The biologic function of TAAs in both germ lines
and tumors has remained poorly understood. It has been
demonstrated that MAGE-A TAAs family represses ge-
nes that are necessary for differentiation20. These genes
have a strong immunogenic potential in humans; they
induce cellular and humoral immune responses and be-
long to the cancer/testis (C/T) gene group21–24. New ther-
apeutic strategies with limited side effects, such as im-
munotherapy, are constantly being investigated and have
achieved promising results, and there is a continued
need to develop more effective cancer immunotherapy
strategies.
Materials and Methods
This is a retrospective study which included sample
from a total of 80 unselected patients with adenocarci-
noma and squamous cell lung carcinoma. These samples
were derived from patients operated at the Department
of Thoracic Surgery, Jordanovac Clinical Hospital for
Pulmonary Diseases in Zagreb, Croatia, during the pe-
riod from 2002 to 2005.
The patients were identified retrospectively in 2006
from pathological reports at the Departments of Pathol-
ogy at the University Hospital for Tumors and the Uni-
versity Hospital »Sestre Milosrdnice». The patients were
divided in two groups. The first group included 40 pa-
tients with adenocarcinoma, and the second group con-
sisted of the same number of patients with squamous cell
lung carcinoma.
For routine histological analysis the lung cancer tis-
sue resected immediately after surgery was fixed in 10%
buffered formalin and later embedded in paraffin. From
this paraffin-embedded tumor samples 4-mm thick sec-
tions were cut and stained with hematoxylin and eosin
and reviewed by the pathologist in order to establish the
pathohistological diagnosis. From the same archival, for-
malin-fixed, paraffin-embedded tumor tissue blocks ad-
ditional serial 5-mm sections were prepared for immuno-
histochemical staining.
The expression of MAGE-A3/4 and NY-ESO-1 in pri-
mary bronchial cancer tissues was studied by immuno-
histochemistry with the addition of undiluted mono-
clonal antibodies (mab). Expression of MAGE-A3/4 was
determined by mab 57B25,26 and of NY-ESO-1 by mab
B9.8.1.1.27.
Briefly, paraffin-embedded tumor tissue slices (2–3)
were used for the immunohistochemical method. The
slices were placed on silane-treated microscope glass
slides (3-aminopropyltriethoxysilane, Sigma, St. Louis,
Mo.). After deparaffinization, the slices were heated in
an 800 W microwave oven at maximum power for 8.5
minutes, held in the 10 mmol/L citrate buffer (pH 6.0) for
5 minutes, and then rinsed with a phosphate buffer solu-
tion (PBS, pH 7.2). This was followed by spraying them
with H2O2 to suppress endogenous peroxidase activity.
After additional rinsing with PBS, the slices were incu-
bated with a 1:10 dilution of normal rabbit serum (Dako
A/S) in a wet chamber at room temperature for 20 min-
utes to prevent non-specific binding of immunoglobulin.
This was followed by the application of monoclonal anti-
bodies specific for MAGE-A1, MAGE-A3/4 and NY-ESO-
-1 in the undiluted form at room temperature for 90 min-
utes. Slices were then treated with biotinilized secondary
antibodies (Dako-No.K0690) for 30 minutes, and this
was followed by rinsing with PBS. The reaction was visu-
alized using Kromogen-DAB (3,5-diaminobenzidine) for
5 minutes. Slices were rinsed with distilled water and
Hemalaun (Dako-No.S2020) was added for 1 minute. Af-
ter rinsing with water and dehydration (96% alcohol),
slices were treated with xilol and fitted in Canada balsam.
The results of the immunohistochemical analysis were
determined by a semi-quantitative method on at least
100 tumor cells. Primary melanoma samples were used
as positive control, as they give positive reaction. If no tu-
mor cell showed staining in the cytoplasm, the reaction
was considered as negative (–). Also, when immuno-
staining was observed in 0–10% of cells (+, weak), it was
also considered as negative in this study. The samples, in
which 11–50% of the tumor cells were positive (++, mod-
erate), and the samples, in which over 50% of the tumor
cells were positive (+++, strong), were considered to be
positive (Figures 1–2).
Fibroblasts and other normal cells were used as nega-
tive controls as they show no immunostaining. Intra-
tumoral necrosis was assessed based on the criteria of
presence (+) or absence (–) in the histopathology report
after surgery of each patient. The differentiation of tu-
mor cells was assessed based on accepted pathohistolo-
gical indicators28.
Distributions of the tested features were shown both
in tables and graphically, in which descriptive statistical
methods were used. The method used in the statistical
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significance testing of the relationship among quantita-
tive features was the c2 test, that is, the Fisher’s exact
test when necessary, at the 0.05 significance level.
Results
This study included 64 (80%) male and 16 (20%) fe-
male patients with non-small cell bronchial cancer, with
a median age of 60 years (35–88) (Table 1). Adenocar-
cinoma and planocellular carcinoma were equally repre-
sented in this study (40 patients in each group). The tu-
mor was well-differentiated in 15%, moderately differen-
tiated in 35% and poorly differentiated in 55% of pa-
tients. The largest number of patients was in stage IIIA
(37.5%), followed by stage IB (26.3%), IIB (15%) and IIIB
(10%). Lymph node status was negative in 47.5% of pa-
tients, positive hilar lymph nodes were found in 16.3%
and positive mediastinal lymph nodes were noted in
36.3% of patients. There was no statistically significant
difference between lymph node status and both tumor
types (p=0,330). Tumor necrosis was found in 53.8% of
patients, and there was no statistically significant differ-
ence between both tumor types (p=0,960). Squamous
cell carcinoma was more frequently classified as grade III
(p=0.002).
All clinical-pathological features in patients are shown
in Table 1.
A possible association between the immunohistoche-
mical expression of MAGE-A3/4 and NY-ESO-1 antigens
and the clinical-pathological features of adenocarcinoma
and planocellular lung carcinoma including patients’ age
and sex, histological tumor type, differentiation grade,
tumor size, lymph node status, presence of tumor necro-
sis and tumor stage is presented in Table 2.
Table 2 Comparison of the expression of MAGE-A3/4
and NY-ESO-1 with regard to clinical-pathological fea-
tures in patients with adenocarcinoma and squamous
cell lung carcinoma
In this series, most of non-small cell lung cancer spec-
imens expressed at least 1 C/T TAA. MAGE-A3/4 and
NY-ESO-1 positive staining was observed in 65.1% and
23.3% of squamous cell carcinomas and 18.9% and 10.8%
of adenocarcinomas, respectively.
No statistically significant difference between male
and female patients in the immunohistochemical expres-
sion of MAGE-A3/4 and NY-ESO-1 in adenocarcinoma
(p=1,000, p=1.000) and squamous cell lung cancer (p=1,000,
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Fig. 1. MAGE-A3/4 strong positive reaction in the cytoplasm of
squamous cell lung cancer.
Fig. 2. NY-ESO-1 strong positive reaction in the cytoplasm of
squamous cell lung cancer.
TABLE 1
CLINICAL-PATHOLOGICAL FEATURES IN PATIENTS WITH
PLANOCELLULAR CANCER (40) AND ADENOCARCINOMA (40)
Variable n
%







































































p=0.280) was found. A statistically higher MAGE-A3/4
expression was observed in squamous cell lung carci-
noma (p<0.001), while no difference was found in the ex-
pression of NY-ESO-1 in adenocarcinoma and squamous
cell carcinoma (Table 2). Furthermore, no significant as-
sociation was found between the MAGE-A3/4 antigen ex-
pression and tumor grade and positive lymph node find-
ing in both histological tumor types. It is interesting that
a significant association was found between the MAGE-A3/4
expression and presence of tumor necrosis in squamous
cell cancer specimens (p=0.001), but not in adenocarci-
noma (p=0.033) (Table 2).
The NY-ESO-1 expression in both adenocarcinoma
and aquamous cell carcinoma showed no significant asso-
ciation with tumor size (p=0.798, p=0.981), differentiat-
ion grade (p=129, p=1.000) and tumor necrosis (p=1.000,
p=0.437). A statistically significant association was noted
between the NY-ESO-1 expression and positive hilar and
mediastinal lymph nodes in adenocarcinoma (p=0.025)
whereas it was not the case in squamous cell carcinoma
(Table 2). No statistically significant correlation among
the concurrent expression of two tumor antigens was
found in either histological tumor types.
Smoking history showed no statistically significant as-
sociation with a higher expression level of any of two tumor
antigens, regardless of the pathohistological tumor type.
Discussion
C/T antigens are not expressed in normal tissues ex-
cept for testis, ovary and placenta that express no MHC
(Major Histocompatibility Complex) class I molecules,
but are expressed in variable proportions of a wide range
of different types of tumors, such as melanomas, cervical
carcinoma, lung and breast carcinomas. Therefore, the
CT antigens are promising targets for cancer immuno-
therapy.
Lung cancer is the most common cause of death from
malignant tumors in men around the world and its inci-
dence among women is growing rapidly. The most dis-
couraging is the overall 15% 5-year survival rate for
those diagnosed with lung cancer2,6. When compared to
the spectrum of other malignancies, the dismal survival
rate for lung cancer is approximated only by that of pan-
creatic cancer1. Cancer incidence rates in the Republic of
Croatia show lung cancer ranking first in men (21%) and
third in women (7%). In 2004, there were 2,119 new
cases and 2,123 lung cancer deaths in men and 534 new
cases and 512 lung cancer deaths in women29.
All clinical prognostic factors in lung cancer accepted
so far are still insufficient for a reliable prediction of the
course of the disease. It is due to the insufficient knowl-
edge of the real biological behavior of tumors. Deter-
mining the tumor differentiation grade and other patho-
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TABLE 2
COMPARISON OF THE EXPRESSION OF MAGE-A3/4 AND NY-ESO-1 WITH REGARD TO CLINICAL-PATHOLOGICAL FEATURES










































































































































histological indicators can only partly indicate the disease
prognosis and therapy selection.
In this paper, we determined the expression of MAGE-
-A3/4 and NY-ESO-1 antigens in a total of 80 patients, of
whom 40 had adenocarcinoma and 40 patients had squ-
amous cell carcinoma.
According to the largest number of studies, the MAGE
gene expression was observed in about 30–50% of non-
-small cell lung cancer tissue samples30,31, and our data
concurs with the results of these studies.
In patients affected by non-small cell lung cancer,
multitissue arrays identified the expression of MAGE-A
as an independent negative prognostic factor32. Other
studies confirmed an inverse correlation between MAGE-
-A3/4 expression and patient survival in advanced stage
lung cancers15, and MAGE-A activation probably takes
place very early in the carcinogenesis of lung cancer33,34.
The expression rate of MAGE-A3/4 did not appear to
vary significant with lymph node status and tumor gra-
de, and there was no significant correlation between the
NY-ESO-1 expression and presence of tumor necrosis.
It is interesting here to see the results in our study of
the statistically significant association among the intra-
tumoral necrosis of the squamous cell carcinoma and a
higher expression of MAGE-A3/4. A similar observation
is found in the association between a higher incidence of
positive lymph nodes and NY-ESO-1 expression. Such a
correlation between necrosis and C/T TAA expression
can testify to their association with more rapidly growing
tumors not accompanied by adequate neovascularization,
which results in the necrosis of the neoplasm tissue. A simi-
lar conclusion could apply to a higher incidence of meta-
stases in the hilar and mediastinal lymph nodes. These
observations suggest that MAGE A-3/4 and NY-ESO-1
are involved in the early steps of tumor progression.
These data suggest that evaluation of the MAGE-A3/4
protein expression is useful in the identification of gro-
ups of NSCLC characterized by severe prognosis, thus
possibly providing indications for early MAGE TAAs-tar-
geted immunotherapy35. To date, only one clinical study
using MAGE-A3 protein as a vaccine has been repor-
ted36. It is shown that vaccination with the recombinant
protein of CT antigens provides strong Ag-specific CD4+
T cell help along with antibodies and CD8+ T cell re-
sponses, and leads to integrated immunity37.
MAGE-A3/4 and NY-ESO-1 were expressed in the
great majority of samples examined. In association with
the recognized characteristic of having strong antigenic
properties, this makes these TAAs very attractive for tri-
als on immunotherapy. The heterogeneous expression of
these antigens suggests that future immunotherapy tri-
als in lung cancer patients will have to adopt use of
polyvalent vaccines.
In conclusion, lung cancer frequently expresses MAGE-
-A3/4 and NY-ESO-1. As C/T antigens are important for
inducing a specific immune reaction in lung cancer pa-
tients, there is an intention to form a subgroup of pa-
tients in the future, whose treatment would be enhanced
by specific immunotherapy based on the observed scien-
tific results. More studies are necessary to define the pos-
sible role of these antigens as immunotherapy targets.
The results revealing high expression levels of two re-
searched C/T TAAs in most paraffin-based samples of
planocellular and lung adenocarcinoma favor the hy-
pothesis that these patients might benefit from active
specific immunization38, and the results shown in this
paper might be useful in the development of new tumor
treatment strategies (multimodal treatment or polyva-
lent vaccines) using C/T TAA gene products, and also in
the prevention of lung cancer 39.
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IMUNOHISTOKEMIJSKA IZRA@ENOSTI CANCER/TESTIS ANTIGENA (MAGE-A3/4, NY-ESO-1) U
BOLESNIKA S RAKOM PLU]A NEMALIH STANICA : POVEZANOST SA KLINI^KO PATOLO[KIM
POKAZATELJIMA
S A @ E T A K
U ovom radu ispitivali smo zna~enje imunohistokemijske izra`enosti MAGE-A3/4 i NY-ESO-1 antigena u usporedbi
sa klini~ko-patolo{kim obilje`jima karcinoma plo~astih stanica i adenokarcinoma plu}a. Produkti MAGE (Melanoma
antigen E) obitelji gena te NY-ESO-1 (New York Oesophageal Squamous Cell Cancer) spadaju u skupinu tumor-pri-
dru`enih antigena (Tumor Associated Antigens – TAAs) i imaju sna`an imunogeni potencijal u ljudi. Normalno su
izra`eni u gametama i trofoblastima, a samo su iznimno u drugim zdravim tkivima. Izra`eni su u brojnim ljudskim
novotvorinama, me|u kojim je i rak plu}a. Imunohistokemijsko odre|ivanje C/T antigena relevantna je metoda za
odre|ivanje njihove ekspresije u raka plu}a. Kako su C/T antigeni va`ni za izazivanje specifi~ne imunosne reakcije u
bolesnika s rakom plu}a, u budu}nosti }e se nastojati odrediti podskupina bolesnika ~ije bi lije~enje bilo unaprije|eno
specifi~nom imunoterapijom temeljem dobivenih znanstvenih rezultata. U studiju je uklju~eno 80 bolesnika s rakom
plu}a nemalih stanica (40 adenokarcinom, 40 karcinom plo~astih stanica) operiranih u razdoblju od 2002.–2005.g.
Ekspresija MAGE-A3/4 antigena odre|ivana je imunohistokemijski primjenom monklonskih protutijela 57B Mab (dr.G.
Spagnoli, Research Laboratory, Basel, Switzerland), a ekspresija NY-ESO-1 monoklonskim protutijelom B9.8.1.1 mAb
(dr.G. Spagnoli, Research Laboratory, Basel, Switzerland). Prisustvo ekspresije ovih C/T antigena uspore|ivano je sa
klini~ko-patolo{kim obilje`jima tumora. Prosje~na dob bolesnika bila je 60 g. (raspon 35-88). Karcinom plo~astih sta-
nica ~e{}e je klasificiran kao gradus 3. Statisti~ki je zna~ajna ve}a imunohistokemijska izra`enost MAGE-A3/4 na|ena
kod planocelularnog karcinoma bronha (p<0,001). Nije na|ena povezanost izme|u veli~ine tumora i izra`enosti sva tri
tumorska antigena. Ekspresija MAGE-A3/4 bila je statisti~ki zna~ajnija u karcinoma plo~astih stanica (p=0,001), a i
zamije~en je zna~ajno ve}i udio tumorske nekroze kod tumora sa ekspresijom MAGE-A3/4 (p=0,001), ali nije na|ena
povezanost sa pozitivnim limfnim ~vorovima. Nadalje, zna~ajna je povezanost ekspresije NY-ESO-1 sa nalazom pozitiv-
nih limfnih ~vorova u adenokarcinoma, ali ne i u karcinoma plo~astih stanica. Kako su C/T antigeni va`ni za izazivanje
specifi~ne imunosne reakcije u bolesnika s rakom plu}a, u budu}nosti }e se nastojati odrediti podskupina bolesnika ~ije
bi lije~enje bilo unaprije|eno specifi~nom imunoterapijom temeljem dobivenih znanstvenih rezultata. Nalaz bi visokog
postotka izra`enosti sva tri istra`ivana C/T TAA u ve~ini parafinskih uzoraka planocelularnog i adenokarcinoma plu}a
govori u prilog hipotezi da bi ti bolesnici mogli imati koristi od aktivne specifi~ne imunizacije, a rezultati prikazani u
ovom radu mogli bi biti korisni u razvoju novih tumorskih cjepiva koriste}i produkte C/T TAA gena, ne samo za lije-
~enje nego i za prevenciju raka plu}a. Ova studija podr`ava rezultate ranijih imunohistokemijskih studija koje su po-
kazale da bi ekspresija MAGE-3 i NY-ESO-1 u bolesnika sa rakom plu}a nemalih stanica mogla vrijedan prognosti~ki
~imbenik te pomo}i u odre|ivanju podskupine bolesnika koji bi imali koristi od imunolo{ke terapije.
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